WO2003018042A1 - Compositions for treatment and prevention of cold having antiviral activity - Google Patents

Compositions for treatment and prevention of cold having antiviral activity Download PDF

Info

Publication number
WO2003018042A1
WO2003018042A1 PCT/KR2002/001603 KR0201603W WO03018042A1 WO 2003018042 A1 WO2003018042 A1 WO 2003018042A1 KR 0201603 W KR0201603 W KR 0201603W WO 03018042 A1 WO03018042 A1 WO 03018042A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
oil
ranges
amount
cold
Prior art date
Application number
PCT/KR2002/001603
Other languages
French (fr)
Inventor
Man-Chul Suh
Original Assignee
Biomedics Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedics Co., Ltd. filed Critical Biomedics Co., Ltd.
Publication of WO2003018042A1 publication Critical patent/WO2003018042A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • the present invention relates to an antiviral composition for treating or preventing cold caused by viral infection.
  • Cold is mainly caused by contaminated air with various viruses such as rhinovirus, adenovirus, RS virus, influenza virus and become worse by various microbes to give rise to complex syndrome such as cough, nose dripping, headache, high fever, chill, sore throat, sneezing, diarrhea, myodinia etc.
  • viruses such as rhinovirus, adenovirus, RS virus, influenza virus
  • complex syndrome such as cough, nose dripping, headache, high fever, chill, sore throat, sneezing, diarrhea, myodinia etc.
  • influenza virus induce upper respiratory tract ache, headache, abdominal; pain, chill, muscular debility and so on.
  • Influenza is caused by several types of myxoviruses, categorized as group A, B, and C 4 .
  • Rhinovirus has too many antigenic types, so it is hard to develop its vaccine. The virus survives in epithelial cell of upper respiratory tract for a long period ranging 4 days to 2 weeks not entering into inner human body. It is not so harmful to induce pneumonia or often to the death, and is symbiotic virus permitting its multiplication easily, which causes acute respiratory disease such as asthma, chronic bronchitis (Johnson S. L. et al, Am. J.
  • Adenovirus causes mainly to throat disease such as sore throat, headache and muscular pain and has strong virulence to the extent to occupy 5 to 10% of infant cold and 70% of respiratory cold in winter.
  • RS virus causes to become inflammation in lower respiratory tract of infant or children, particularly, induces pneumonia and bronchitis of infant less than 1 year old and occupy with 50% in origin of the disease.
  • Corona virus causes to adult's cold happened in winter occupying the ratio of 10 to 30% and lies dormant for a period of 2 or 5 days which continues about for 1 week.
  • cold fundamentally and injection vaccine known to be one of the effective treating agent can treat only about 70 to 90% of the patients, however it is also not so satisfying drug since there are too many antigenic types virus not treated by the drug.
  • the symptomatic treatment by alleviating cold symptom has been known in the art using by various antipyretics, antMstamines and the like, however, they also do not satisfy fundamental treatment.
  • Fenugreek extract extracted from Chinese plant (Trigonella foenum- graceum L.), is known to have protective effect of gastro-mtestinal tract.
  • Clove leaf oil extracted from Indonesian plant (Eugenia aromatica L), is known to be effective to treat anxiety and headache.
  • Camphor crystal consists of 50% of menthol and is extracted from
  • composition comprising thyme essential oil, eucalyptus essential oil, camphor crystal, L-menthol, methyl salicylate Fenugreek extract, Patchouli oil and clove leaf oil as an effective ingredient for treating or preventing cold.
  • Another object of the present invention is to provide an antiseptic composition
  • an antiseptic composition comprising thyme essential oil, eucalyptus essential oil, camphor crystal, L-menthol, methyl salicylate Fenugreek extract, Patchouli oil and clove leaf oil as an effective ingredient.
  • inventive composition comprise about 5 to 35% thyme oil, 1 to 25% methyl salicylate, 5 to 45% Eucalyptus oil, 2 to 25% camphor crystal, 1 to 15% menthol, 1 to 15% Fenugreek extract, 1 to 25% Patchouli extract and 1 to 25% clove leaf oil by weight.
  • the amount of Patchouli extract and clove leaf oil is ranging from 5 to 25 w/w% of total amount of inventive composition.
  • suitably applicable types of product such as spray, fumigates, desirably, fumigates containing said composition for preventing or treating cold.
  • Inventive fumigates is intended to administrate above composition to human body by way of heating the solution by electric apparatus or other suitable apparatus to evaporate effective composition and reach to human body rapidly and conveniently, which can treat cold caused by influenza by acting on epithelial cells of human upper respiratory tract.
  • treating or preventing method using by " above composition to prevent or treat cold caused by cold are also provided.
  • antiseptic method using by above composition to kill microbe, fungi and virus in air, and the influenza virus in human epithelial cells.
  • the diluents for example, alcohol such as ethanol or glycol such as dipropylene glycol
  • the apparatus to transfer said composition to a respiratory organ or ear can be adopted any means known in the art.
  • Said apparatus may comprise any means comprising inhaler, vaporizer, dropper, nasal spray type apparatus in order to transfer to nose, mouth, respiratory tract, lung, ear and/or cavity in human.
  • Said composition further comprise distilled water, surfactant, coloring agents, fragrance such as monohydric and polyhydric alcohol, preservative and so on.
  • Inventive composition may be used by being poured into administration reservoir in the amount of 50 to 90w/w%, preferably, 60 to 80w/w% of reservoir weight and the administration level may be changed according to the eight, ages, sex, health condition and the severity of disease of each patient.
  • the following Reference Example, Example and Test Example are intended to further illustrate the present invention without limiting its scope.
  • Test Example Activities of compositions in Example 1 to 4.
  • group A, B, C and D consisting of 30 patients respectively.
  • the patients in group A were suffered from coryza symptom such as nose dripping, cough and so on, which was presumed to be infected by rhinovirus
  • group B were suffered from sore throat, myalgia and fever, which was presumed to be infected by adenovirus
  • group C were infected by Corona virus
  • group D were infected by influenza virus.
  • composition prepared by Examples 1 to 4 i.e., each 185/zg, 380 zg, 780/zg, 1.58mg, 3.13mg, 8.25mg, 12.5mg, 25mg, 50mg and lOOmg, were dissolved in 40m# of solvent such as ethanol or dipropyleneglycol.
  • Example 4 showed strong inhibition at the concentration range from 1.56 mg to lOOmg, the composition in Example 2 showed strong inhibition range from 12.5mg to lOOmg and the composition in Example 3 showed strong inhibition range from 25mg to lOOmg, which can confirm the antiviral activity of present composition.
  • inventive composition comprising thyme essential oil, eucalyptus essential oil, camphor crystal, L-menthol, methyl salicylate Fenugreek extract, Patchouli oil and clove leaf oil showed strong activity to treat cold caused by various influenza viruses, it can be useful not only to prevent or treat infant or adult cold but also to clean all the contaminant in an ⁇ as a form of applicable dosage form such as spray and fumigate.

Abstract

The present invention relates to an antiviral composition. In particular, the present invention relates to antiviral composition comprising thyme essential oil, eucalyptus essential oil, camphor crystal, L-menthol, methyl salicylate,Fenugreek extract, Patchouli oil and clove leaf oil. The present invention shows strong antiviral activities against various influenza viruses, therefore, said plant oils, extracts and compounds are expected to be useful as antiviral composition.

Description

COMPOSITIONS FOR TREATMENT AND PREVENTION OF COLD HAVING ANTIVIRAL ACTIVITY
TECHNICAL FIELD The present invention relates to an antiviral composition for treating or preventing cold caused by viral infection.
BACKGROUND OF ART
Cold is mainly caused by contaminated air with various viruses such as rhinovirus, adenovirus, RS virus, influenza virus and become worse by various microbes to give rise to complex syndrome such as cough, nose dripping, headache, high fever, chill, sore throat, sneezing, diarrhea, myodinia etc.
Among the viruses, influenza virus induce upper respiratory tract ache, headache, abdominal; pain, chill, muscular debility and so on. Influenza is caused by several types of myxoviruses, categorized as group A, B, and C4.
These influenza viruses generally lead to similar symptoms but are completely unrelated antigenically, so that infection with one type confers no immunity against the other (Gwaltney, J. M. et al., N. Eng. J. Med., 275, ppl261-1268, 1966). Rhinovirus has too many antigenic types, so it is hard to develop its vaccine. The virus survives in epithelial cell of upper respiratory tract for a long period ranging 4 days to 2 weeks not entering into inner human body. It is not so harmful to induce pneumonia or often to the death, and is symbiotic virus permitting its multiplication easily, which causes acute respiratory disease such as asthma, chronic bronchitis (Johnson S. L. et al, Am. J.
Respira. Crit. Care Med. 154, pp654-660, 1996; Johnson, S. L. et al, Br. Med.
J. 310, ppl225-1228, 1995). Adenovirus causes mainly to throat disease such as sore throat, headache and muscular pain and has strong virulence to the extent to occupy 5 to 10% of infant cold and 70% of respiratory cold in winter.
RS virus causes to become inflammation in lower respiratory tract of infant or children, particularly, induces pneumonia and bronchitis of infant less than 1 year old and occupy with 50% in origin of the disease.
Corona virus causes to adult's cold happened in winter occupying the ratio of 10 to 30% and lies dormant for a period of 2 or 5 days which continues about for 1 week. However, there has been not yet reported to treat cold fundamentally and injection vaccine known to be one of the effective treating agent, can treat only about 70 to 90% of the patients, however it is also not so satisfying drug since there are too many antigenic types virus not treated by the drug.
Moreover, the symptomatic treatment by alleviating cold symptom has been known in the art using by various antipyretics, antMstamines and the like, however, they also do not satisfy fundamental treatment.
Thyme essential oil extracted from Spanish plant (Thym s zygis L) belonging to Labiatae family, is known to treat neuronal disease such as neuronal headache and depression, fatigue, anemia and the like and stimulate gastrointestinal digestion.
Eucalyptus essential oil extracted from Spanish plant {Eucalyptus globules L.), is known to be helpful to refresh air and to intensify psychological concentration.
Fenugreek extract extracted from Chinese plant (Trigonella foenum- graceum L.), is known to have protective effect of gastro-mtestinal tract.
(Chung, B. S. et al, (1998) DOHAEHYANGYAKDAISAJEON (Plant part), Youngrim Press, pp711 -712) . Patchouli oil extracted from Indonesian plant belonged to Pogostemon family, is known to have antibacterial activity and expectorant activity through respiratory tract.
Clove leaf oil extracted from Indonesian plant (Eugenia aromatica L), is known to be effective to treat anxiety and headache.
Camphor crystal consists of 50% of menthol and is extracted from
Chinese plant (Mentha piperita L). Camphor oil extracted from Chinese plant
(Cinnamomum camphora L), is known to be effective to treat headache and allergic disease (Chung, B. S. et al, (1998) DOHAEHYANGYAKDAISAJEON (Plant part), Youngrim Press, pp851-852).
DISCLOSURE OF THE INVENTION
Accordingly, it is an object of the present invention to provide a composition comprising thyme essential oil, eucalyptus essential oil, camphor crystal, L-menthol, methyl salicylate Fenugreek extract, Patchouli oil and clove leaf oil as an effective ingredient for treating or preventing cold.
Another object of the present invention is to provide an antiseptic composition comprising thyme essential oil, eucalyptus essential oil, camphor crystal, L-menthol, methyl salicylate Fenugreek extract, Patchouli oil and clove leaf oil as an effective ingredient.
It is preferred that inventive composition comprise about 5 to 35% thyme oil, 1 to 25% methyl salicylate, 5 to 45% Eucalyptus oil, 2 to 25% camphor crystal, 1 to 15% menthol, 1 to 15% Fenugreek extract, 1 to 25% Patchouli extract and 1 to 25% clove leaf oil by weight.
It is also preferred that the amount of Patchouli extract and clove leaf oil is ranging from 5 to 25 w/w% of total amount of inventive composition. In accordance with one aspect of the present invention, there is provided suitably applicable types of product such as spray, fumigates, desirably, fumigates containing said composition for preventing or treating cold. Inventive fumigates is intended to administrate above composition to human body by way of heating the solution by electric apparatus or other suitable apparatus to evaporate effective composition and reach to human body rapidly and conveniently, which can treat cold caused by influenza by acting on epithelial cells of human upper respiratory tract. In accordance with another aspect of the present invention, there are also provided treating or preventing method using by" above composition to prevent or treat cold caused by cold.
In accordance with another aspect of the present invention, there are also provided antiseptic method using by above composition to kill microbe, fungi and virus in air, and the influenza virus in human epithelial cells.
In present invention, the diluents for example, alcohol such as ethanol or glycol such as dipropylene glycol, can be poured into reservoir containing said composition with a ratio ranging from 10 to 50% (w/w% or v/v%) and evaporated by heating. In accordance with present invention, the apparatus to transfer said composition to a respiratory organ or ear, can be adopted any means known in the art. Said apparatus may comprise any means comprising inhaler, vaporizer, dropper, nasal spray type apparatus in order to transfer to nose, mouth, respiratory tract, lung, ear and/or cavity in human. Said composition further comprise distilled water, surfactant, coloring agents, fragrance such as monohydric and polyhydric alcohol, preservative and so on.
Inventive composition may be used by being poured into administration reservoir in the amount of 50 to 90w/w%, preferably, 60 to 80w/w% of reservoir weight and the administration level may be changed according to the eight, ages, sex, health condition and the severity of disease of each patient. The following Reference Example, Example and Test Example are intended to further illustrate the present invention without limiting its scope.
BEST MODE FOR CARRTNG OUT THE INVENTION
The following Examples and Experimental Examples are intended to further illustrate the present invention without limiting its scope.
Example 1
The mixture of 30mg of thyme oil, lOmg of Eucalyptus oil, 7mg of Campor crystal, 7mg of menthol, 5mg of methyl salicylate, 13mg of Fenugreek dried extract, 15mg of Patchouli dried extract purchased from American company (Creative Fragrances Ltd.), was dissolved in 13 m-?- of dipropyleneglycol and admixed with a mixer to prepare lOOuώ of sample solution.
[Table 1] Composition prepared by Example 1
Figure imgf000006_0001
Figure imgf000007_0001
Example 2
The mixture of 25mg of thyme oil, 4mg of Eucalyptus oil, 4mg of Camphor crystal, 7mg of menthol, 5mg of methyl salicylate, 17mg of Clove leaf oil, 23mg of Fenugreek dried extract purchased from American company
(Creative Fragrances Ltd), was dissolved in 15m£ of ethanol and admixed with a mixer to prepare lOOmi of sample solution.
[Table 2] Composition prepared by Example 2.
Figure imgf000007_0002
Example 3
The mixture of 20mg of thyme oil, 5mg of Eucalyptus oil, 5mg of Camphor crystal, 5mg of menthol, 5mg of methyl salicylate, 20mg of Fenugreek oil, 20mg of Clove leaf oil purchased from American company (Creative Fragrances Ltd), was dissolved in
Figure imgf000008_0001
of dipropyleneglycol and admixed with a mixer to prepare 100m£ of sample solution.
[Table 3] Composition prepared by Example 3.
Figure imgf000008_0002
Example 4
The mixture of 30mg of thyme oil, 15mg of Eucalyptus oil, 3mg of Camphor crystal, 3mg of menthol, 5mg of methyl salicylate, 13mg of Fenugreek dried extract and 15mg of Patchouli dried extract purchased from American company (Creative Fragrances Ltd), was dissolved in 16ml of ethanol and admixed with a mixer to prepare lOOm of sample solution.
[Table 4] Composition prepared by Example 4.
Figure imgf000009_0001
Test Example: Activities of compositions in Example 1 to 4.
In present test, 120 patients were categorized as group A, B, C and D consisting of 30 patients respectively. The patients in group A were suffered from coryza symptom such as nose dripping, cough and so on, which was presumed to be infected by rhinovirus, group B were suffered from sore throat, myalgia and fever, which was presumed to be infected by adenovirus, group C were infected by Corona virus and group D were infected by influenza virus.
Various concentrations of composition prepared by Examples 1 to 4, i.e., each 185/zg, 380 zg, 780/zg, 1.58mg, 3.13mg, 8.25mg, 12.5mg, 25mg, 50mg and lOOmg, were dissolved in 40m# of solvent such as ethanol or dipropyleneglycol.
The solutions were inhaled to group A to D patients three times a day, the alleviation value of disease's symptom were analyzed quantitatively, the resulting data was shown in Table 5.
[Table 5] Inhibitory activities of the composition prepared by Examples against various cold viruses.
Figure imgf000010_0001
As can be seen from Table 5, the composition in Example 1 and
Example 4 showed strong inhibition at the concentration range from 1.56 mg to lOOmg, the composition in Example 2 showed strong inhibition range from 12.5mg to lOOmg and the composition in Example 3 showed strong inhibition range from 25mg to lOOmg, which can confirm the antiviral activity of present composition. INDUSTRIAL APPLICABILITY
Since inventive composition comprising thyme essential oil, eucalyptus essential oil, camphor crystal, L-menthol, methyl salicylate Fenugreek extract, Patchouli oil and clove leaf oil showed strong activity to treat cold caused by various influenza viruses, it can be useful not only to prevent or treat infant or adult cold but also to clean all the contaminant in an¬ as a form of applicable dosage form such as spray and fumigate.
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined in the appended claims.

Claims

1. A composition comprising thyme essential oil, eucalyptus essential oil, camphor crystal, L-menthol, methyl salicylate, Fenugreek extract, Patchouli oil and clove leaf oil as an effective ingredient for treating or preventing cold.
2. An antiseptic composition comprising thyme essential oil, eucalyptus essential oil, camphor crystal, L-menthol, methyl salicylate, Fenugreek extract, Patchouli oil and clove leaf oil as an effective ingredient.
3. The composition of claim 1 or 2, wherein the amount of said thyme essential oil ranges from 5 to 35w/w%.
4. The composition of claim 1 or 2, wherein the amount of said methyl salicylate ranges from 1 to 25w/w%.
5. The composition of claim 1 or 2, wherein the amount of said eucalyptus oil ranges from 5 to 45w/w%.
6. The composition of claim 1 or 2, wherein the amount of said camphor crystal ranges from 1 to 25w/w%.
7. The composition of claim 1 or 2, wherein the amount of said menthol ranges from 1 to,25w/w%.
8. The composition of claim 1 or 2, wherein the amount of said Fenugreek extract ranges from 1 to 25w/w%.
9. The composition of claim 1 or 2, wherein the amount of said Patchouli extract ranges from 1 to 25w/w%.
10. The composition of claim 1 or 2, wherein the amount of said clove leaf oil ranges from 1 to 25w/w%.
11. The composition of claim 1 or 2, wherein said composition comprises about 5 to 35% thyme oil, 1 to 25% methyl salicylate, 5 to 45%
Eucalyptus oil, 2 to 25% camphor crystal, 1 to 15% menthol, 1 to 15% Fenugreek extract, 1 to 25% Patchouli extract and 1 to 25% clove leaf oil by weight.
12. A product selected from spray or fumigates containing said composition of claim 1 or 2 for preventing or treating cold.
13. The product of claim 12, wherein said product is form of fumigates.
PCT/KR2002/001603 2001-08-27 2002-08-26 Compositions for treatment and prevention of cold having antiviral activity WO2003018042A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR2001/51926 2001-08-27
KR20010051926 2001-08-27

Publications (1)

Publication Number Publication Date
WO2003018042A1 true WO2003018042A1 (en) 2003-03-06

Family

ID=19713613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2002/001603 WO2003018042A1 (en) 2001-08-27 2002-08-26 Compositions for treatment and prevention of cold having antiviral activity

Country Status (3)

Country Link
KR (1) KR20030019097A (en)
CN (1) CN1537011A (en)
WO (1) WO2003018042A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110153A1 (en) * 2003-06-17 2004-12-23 Henkel Kommanditgesellschaft Auf Aktien Agents against microorganisms, containing patchouli oil, patchouli alcohol and/or the derivatives thereof
DE10327134A1 (en) * 2003-06-17 2005-01-13 Henkel Kgaa Use of patchouli oil, patchouli alcohol or their derivatives to inhibit asexual reproduction of fungi, reduce adhesion of microorganisms to surfaces or prepare compositions for treating microbial infections
CN102697858A (en) * 2012-06-08 2012-10-03 东北农业大学 Application of clove leaves or extract thereof in preparation of swine influenza virus resistant medicament

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100728722B1 (en) * 2005-12-27 2007-06-27 알앤엘생명과학주식회사 Antimicrobial and antiviral composition containing natural products
CN102552390A (en) * 2012-01-11 2012-07-11 延安常泰药业有限责任公司 Application of ground pepper volatile oil in preparation of medicine for preventing cold
CN106236807B (en) * 2016-07-20 2020-08-14 深圳神农特医食品有限公司 Composition for preventing and treating influenza virus and traditional Chinese medicine compound oral instant membrane preparation
KR20190045050A (en) 2018-09-07 2019-05-02 류형준 Food composition for treating cold and flu
KR102077833B1 (en) 2018-12-10 2020-02-14 류형준 Fuctional food compositions
KR20220110669A (en) 2021-01-31 2022-08-09 (주)예스킨 Anti covid-19 agent
KR20220110655A (en) 2021-01-31 2022-08-09 (주)예스킨 Anti covid-19 agent and adjuvant for anti virus agent
CN113975314B (en) * 2021-10-27 2022-05-10 广东罗浮山国药股份有限公司 Application of oil of Liaopo mountain Baicao in preparing medicine for inhibiting infection of coronavirus OC43 and SARS-Cov-2 in vitro

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5455721A (en) * 1977-10-12 1979-05-04 Yamanouchi Pharmaceut Co Ltd Cold remedy for external use
JPH01313062A (en) * 1988-06-14 1989-12-18 Kao Corp External remedy for cold
JPH0597663A (en) * 1991-10-12 1993-04-20 Kanebo Ltd Aspiration type preparation for common cold
KR950013581B1 (en) * 1992-03-13 1995-11-13 주식회사태평양 Aromatic for using humidifier
KR20000001148A (en) * 1998-06-09 2000-01-15 최영신 Essential oil composition having functions of antibiosis and antifungus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861145A (en) * 1997-06-09 1999-01-19 The Procter & Gamble Company Method of reducing body odor using perfumed, odor absorbing, two phase compositions
US6080401A (en) * 1998-11-19 2000-06-27 Reddy; Malireddy S. Herbal and pharmaceutical drugs enhanced with probiotics

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5455721A (en) * 1977-10-12 1979-05-04 Yamanouchi Pharmaceut Co Ltd Cold remedy for external use
JPH01313062A (en) * 1988-06-14 1989-12-18 Kao Corp External remedy for cold
JPH0597663A (en) * 1991-10-12 1993-04-20 Kanebo Ltd Aspiration type preparation for common cold
KR950013581B1 (en) * 1992-03-13 1995-11-13 주식회사태평양 Aromatic for using humidifier
KR20000001148A (en) * 1998-06-09 2000-01-15 최영신 Essential oil composition having functions of antibiosis and antifungus

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110153A1 (en) * 2003-06-17 2004-12-23 Henkel Kommanditgesellschaft Auf Aktien Agents against microorganisms, containing patchouli oil, patchouli alcohol and/or the derivatives thereof
DE10327134A1 (en) * 2003-06-17 2005-01-13 Henkel Kgaa Use of patchouli oil, patchouli alcohol or their derivatives to inhibit asexual reproduction of fungi, reduce adhesion of microorganisms to surfaces or prepare compositions for treating microbial infections
CN102697858A (en) * 2012-06-08 2012-10-03 东北农业大学 Application of clove leaves or extract thereof in preparation of swine influenza virus resistant medicament

Also Published As

Publication number Publication date
KR20030019097A (en) 2003-03-06
CN1537011A (en) 2004-10-13

Similar Documents

Publication Publication Date Title
CN102429840B (en) Mosquito repellent liquid and preparation method thereof
CN105504966B (en) A kind of offset litho printing ink
WO2014023145A1 (en) Mite killing bactericide and method for preparing same
CN106310323A (en) Plant essential oil air freshener
CN105542557A (en) Waterborne UV ink for ink jet printing
CN102512490A (en) Aromatherapy essential oil for treating gynecological inflammation and essential oil aromatherapy patch
WO2003018042A1 (en) Compositions for treatment and prevention of cold having antiviral activity
KR20110050793A (en) Composition for preventing and treating nose disease comprising extract of star anis and aroma oil as active ingredients
CN114246925A (en) Traditional Chinese medicine essential oil and application thereof
CN103263679B (en) The preparation method of the fragrant plant air scavenging solution of medicine of environment purification, strengthening respiratory system
CN106336730A (en) Environment-friendly aqueous black ink
Harris 11 Phytotherapeutic Uses of Essential Oils
CN103083404A (en) Nasal cavity protective agent
CN113785847A (en) A fumigant with effects of eliminating dampness, removing toxic substance and avoiding plague, and its preparation method
CN1276765C (en) Incense fumigating agent for coryza
CN112602732A (en) Epidemic prevention traditional Chinese medicine essential oil formula
CN111012823A (en) Medicine containing lindera glauca volatile oil and administration method thereof
CN113749129A (en) Air freshener and insect repellent liquid and preparation method thereof
CN110742924A (en) Traditional Chinese medicine volatile oil composition and application thereof
CN1215884C (en) Chinese medicine formula for preventing common cold by fumigating air to act respiratory tract and using method
MX2012008419A (en) Improved composition based on terpenoids and chloretone, and the use thereof in nasal items.
KR20230113318A (en) Novel therapeutic composition based on low-dose essential oils
CN106336722A (en) Improved printing ink
CN106189513A (en) Covering type textile inkjet printing pigment ink
CN106349812A (en) Natural water-based oil paint ink

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE CH CY DE DK FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 028120477

Country of ref document: CN

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A OF 12-07-2004)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP